We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Galactooligosaccharides (GOS / B-GOS prebiotic)
One of the most reliably replicated prebiotics on the shelf — GOS raises faecal bifidobacteria in trial after trial, and two meta-analyses agree. The clinical layer above that mechanism is far weaker: the IBS meta-analysis is flatly null on global symptom response, and GOS is itself the oligosaccharide in FODMAP, which puts it in direct tension with the best-evidenced dietary treatment for IBS.
What the evidence says
Galactooligosaccharides helped in about half (2/3) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 2008–2020 with a typical study size of 159 participants.
Based on 10 studies · 2 meta-analyses · 7 RCTs · 4,179 total participants
Confidence
High confidenceWhat the studies found
By outcome
The bifidogenic mechanism is meta-analytically confirmed and replicated across independent trials, which is more than most supplements can show. Everything built on top of that mechanism is weak or self-contradictory: the IBS meta-analysis is null on global response, the one IBS trial that worked showed an inverted dose-response, and the trial that combined GOS with a low-FODMAP diet found symptoms improved while bifidobacteria fell.
8 trials ongoing or recruiting · 13 completed on ClinicalTrials.gov
1 of the completed trials have posted results
Registered trials show research momentum for Galactooligosaccharides, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for Galactooligosaccharides meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
Not authorised by EFSA
“Galacto-oligosaccharides Helps support a healthy immune system in an ageing population”
“Galacto-oligosaccharides Helps to manage the symptoms associated with irritable bowel syndrome”
“Galacto-oligosaccharides Energises your immunity boosting bacteria Helps boost your body's self defence”
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
GOS has an unusually clean mechanistic record and an unusually messy clinical one, and the honest way to read it is to keep those two layers apart.
The bifidogenic effect is about as well established as any claim on this site: a meta-analysis of dietary fibre trials in healthy adults found galacto-oligosaccharides among the fibre types that significantly raised both Bifidobacterium and Lactobacillus, and a separate meta-analysis in irritable bowel syndrome and other functional bowel disorders confirmed prebiotics raise absolute bifidobacteria abundance.
Neither meta-analysis found any effect on overall microbial diversity. That is where the good news stops.
The same IBS meta-analysis found no difference at all between prebiotics and placebo on global symptom response — 54% responded on prebiotic versus 63% on placebo, an odds ratio of 0.62 with a confidence interval spanning almost two orders of magnitude — and no benefit for abdominal pain, bloating or quality of life.
The individual trials do not line up any better. In the dedicated GOS trial in IBS, the LOWER 3.5 g/d dose improved more symptoms than 7 g/d, an inverted dose-response that a real pharmacological effect should not show.
In the one trial where GOS was given alongside a low-FODMAP diet and symptom relief was clearly better than sham, bifidobacteria went DOWN rather than up — the proposed mechanism and the observed outcome came apart in the same study.
The traveller's-diarrhoea evidence has the same shape: the larger of the two trials was significant only in its per-protocol analysis and not in the more conservative conditionally-evaluable one, and the entire effect sat in one-day, self-limiting episodes with no change in duration or severity.
The immune findings in older adults are internally mixed — the same trial that raised IL-10 and natural-killer activity also raised C-reactive protein — and in students the gastrointestinal and cold-or-flu benefit was absent in overweight and obese participants.
The point that most matters practically is a definitional one: GOS is the 'O' in FODMAP — it IS the oligosaccharide class that the low-FODMAP diet restricts.
Recommending it to someone with IBS is therefore in direct tension with the best-evidenced dietary intervention for that condition, and the single trial that combined the two is not a resolution of that tension so much as an illustration of it.
GOS resists digestion in the small intestine and is selectively fermented by colonic bifidobacteria. This is the best-supported thing about the compound: two meta-analyses confirm the increase in Bifidobacterium, though neither found any change in overall microbial diversity.
Rapid colonic fermentation is not a separate side effect from the mechanism — it IS the mechanism. GOS is the oligosaccharide in FODMAP, the class of carbohydrates the low-FODMAP diet removes precisely because fermenting them provokes symptoms in sensitive people.
Two crossover trials in healthy elderly volunteers reported higher phagocytosis, natural-killer cell activity and IL-10 with GOS. The evidence is not one-directional: the later trial also recorded higher C-reactive protein alongside those changes.
How Galactooligosaccharides works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
This is the population with both the most GOS research and the least resolved answer. The meta-analysis found no global symptom response, the dedicated GOS trial found the lower dose worked better, and GOS is itself a FODMAP. If you are on or considering a low-FODMAP diet, treat GOS as working against it and involve your dietitian.
The evidence is weaker than it is usually presented. The larger trial was significant only per-protocol, non-significant in the conservative analysis, and its effect was entirely in one-day self-limiting diarrhoea with no change in duration or severity. It is not a substitute for food and water precautions.
No trial of supplemental GOS in pregnancy or lactation is cited here. Not established either way.
Not a drug-level interaction — the effect is additive fermentation. Lactulose is a non-digestible, colonically fermented sugar like GOS itself, so the two fermentable loads add together and produce more gas, flatulence, bloating and looser stools. Do not start both at once; introduce one at a time and at the low end of the range.
Tip: Reduce the dose rather than raising it — the IBS trial found 3.5 g/d improved flatulence and bloating where 7 g/d did not
Tip: Start at 1.4-2.5 g/day and hold there for 1-2 weeks
Galactooligosaccharides has an evidence score of 5/10 — moderate evidence based on 74 indexed studies, including 2 meta-analyses. One of the most reliably replicated prebiotics on the shelf — GOS raises faecal bifidobacteria in trial after trial, and two meta-analyses agree. The clinical layer above that mechanism is far weaker: the IBS meta-analysis is flatly null on global symptom response, and GOS is itself the oligosaccharide in FODMAP, which puts it in direct tension with the best-evidenced dietary treatment for IBS. Representative study: PMID 30949662.
The commonly studied dose of Galactooligosaccharides is 3.5-5.5 g/day. Going higher is not supported: in the one IBS trial, 3.5 g/d improved more symptoms than 7 g/d, and in stressed students 2.5 g lowered cold-or-flu symptom scores across all stress levels while 5 g helped only at lower stress. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Galactooligosaccharides is with meals. Take it with food. No trial compared timings.
Galactooligosaccharides is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are flatulence and bloating, abdominal discomfort or altered stool consistency. Use caution if any of these apply to you: Strict low-FODMAP diet — GOS is one of the oligosaccharides that diet removes; Active symptom flare in FODMAP-sensitive IBS.
Lactoferrin
Mostly mechanism / observationalA multifunctional iron-binding glycoprotein from milk with broad antimicrobial, anti-inflammatory, and immune-modulating properties.
Colostrum
Likely helpsFirst milk rich in immunoglobulins, growth factors, and antimicrobial compounds that supports gut health, immunity, and recovery.
Beta-Glucans
Likely helpsPolysaccharides from yeast, mushrooms, or oats that train innate immune cells to respond faster to infections and pathogens.
Peppermint Oil
Mostly mechanism / observationalEnteric-coated peppermint oil is one of the better-evidenced botanicals in gastroenterology — multiple meta-analyses of randomized trials show it relieves global symptoms and abdominal pain in irritable bowel syndrome (IBS), with smaller but consistent signals for functional dyspepsia (combined with caraway oil). It is an antispasmodic, not a cure.
Explore: Best supplements for Body HealthBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 10 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research